Epidemiological studies have shown that the two hMPV genotypes alternate in predominance worldwide in recent years. Co-circulation of the two genotypes of hMPV was usually observed and there is no study about the interaction between them, such as competitive replication, which maybe the possible mechanisms for alternating prevalence of subtypes. Our present study have used two different genotypes of hMPV (genotype A: NL/1/00; B: NL/1/99) in different proportions in animal model (BALB/c mice) and cell model (Vero-E6) separately. The result showed that the competitive growth does exist in BALB/c mice, genotype B had a strong competitive advantage. However, genotype B did not cause more severe disease than non-predominant (genotype A) or mixed strains in the study, which were evaluated by the body weight, airway hyperresponsiveness and lung pathology of mouse. In cell model, competitive growth and the two genotypes alternately prevalence were observed. In summary, we confirmed that there was a competitive replication between hMPV genotype A and B, and no difference in disease severity caused by the two subtypes. This study shows a new insight to understand the alternation of hMPV genotype prevalence through genotype competition and provide experimental evidence for disease control and vaccine design.
Results
In vivo competitive growth experiment. To determine whether competitive replication occurred in vivo, we divided the mice into six groups. Three groups were given nasal drops with different proportions of mixed strains (genotype A:B) as 50:50, 20:80 and 80:20; Two groups dropped with genotype A and genotype B; one group dropped with DMEM (Virus preservation solution) as control group. If the copy numbers were too low, the detection accuracy could not be guaranteed. When the virus copy numbers in the lung were less than 10 3 , the competitive experiment was terminated. A similar alternation in terms of the predomination of genotypes A and B could be seen in the mouse model. When A:B = 50:50 ( Fig. 1A) , the proportion of genotype A decreased from day 1 to 8, but after day 8, it increased from 4.54% (day 6) to 63.74% (day 17); by day 20, it had decreased to 44.90%, and genotype B was predominant.
After the adjustment of the input ratio of the A:B genotypes to 20:80 ( Fig. 1B) , the proportion of A was increased on day 1 and decreased from day 2 to day 8; however, during this process, the proportion of A increased slowly and was higher than 20% on day 13. Regarding the group with an input ratio of 80:20 (Fig. 1C ), the two genotypes alternated in terms of their proportions. The proportion of genotype B increased slowly and was higher than 50% on day 13, but decreased on day 17, then increased to 72% on day 20. In a word, hMPV can only survive for 3 weeks in mice. Regardless of the initial proportion of subtype B, after competing with subtype A, type B would dominate finally and show an absolute growth advantage.
Weight change in mice with hMPV infection. BALB/c mice were infected with 50 μl of hMPV virus (1.0 × 10 9 copies/ml) and were observed daily to measure their weight loss. Starting 1 dpi (days post infection, dpi), the mice began to have ruffled hair that persisted until 6 dpi. Breathing problems appeared 1 to 6 dpi, as well as a slight decrease in physical activity and a tendency to huddle. Significant weight loss appeared 4 dpi (P < 0.05). In the control group, neither weight loss nor respiratory symptoms were observed ( Fig. 2 ). There were no statistically significant differences after 20 days of infection between the groups (in the genotype A alone, genotype B alone and 3 mixed genotype groups) (P > 0.05). Differences only appeared in the infection and control groups on the 2nd day after infection.
The results ( Fig. 4) showed that there were no differences between the control group and any of the infection groups when dosages of methacholine of 3.125 and 6.25 mg/ml were administered (P > 0.05). However, when the concentration of methacholine was higher than 12.5 mg/ml, there was a significant difference between the infection groups and the control group (P < 0.05). At concentrations of 25 and 50 mg/ml, there was significantly higher airway responsiveness in all infection groups than in the control group (P < 0.05). Nevertheless, there were no differences among the five infected groups (P > 0.05).
Histopathological changes in the lungs. Pulmonary inflammation was assessed using a scoring scale system developed by Cimolai et al. 28 . The highest viral load was observed on the fourth day, and the mice were sacrificed on the fifth day to assess the pathological changes. On the 5th day, a few infiltrating cells were found around bronchioles or vessels in non-infected mice, and infected mice showed swelling of the bronchiolar epithelial cells, alveolar dilation and extensive infiltration of lymphocytes and macrophages in both bronchioles and pulmonary blood vessels, indicating a high mean score (Fig. 5A ). The inflammatory responses in the infection groups were significantly more dramatic compared to those in the DMEM control group (P < 0.05). However, there were no differences among the five infected groups (P > 0.05) ( Fig. 5B ). In vitro competitive growth experiment. Vero-E6 cell lines were used for the hMPV competitive experiment in vitro, and the same multiplicity of infection (MOI = 50) was used for all infection groups. There were 5 mixed groups with genotype A:B proportions of 50:50, 20:80, 80:20, 10:100 and 100:10. The cells were passaged every 4 days. The competitive experiment was terminated when one of the genotypes could not be detected for at least three passages.
First, the input ratio of the two genotypes was adjusted to 50:50. Genotype A predominated (99.08%) during the 1st passage, which was followed by a decrease in the 3rd passage, while genotype B was predominant (85.68%) in 3rd passage ( Fig. 6A ). Interestingly, after the 3rd passage, the proportion of genotype A gradually increased from 14.32% (passage 3, P3) to 35.67% (P5) to 98.07% (P6) and then finally to 99.98% (P8) until B could not be detected. Competition replication of this group was from type A to B and genotype A become the predominant strain in the end.
When the hMPV input ratio was adjusted to A:B = 80:20 and 100:10, subtype A account for a larger proportion at first. In Fig. 6C , during P1, the proportion of genotype A increased from 80% to 94.71%. However, at P3, the proportion of B increased, and B predominated (79.19%). Then, the proportion of B decreased from 25.22% (P5) to 1.57% (P6) until B was not detected (P8). A 10-fold difference in the input ratio was utilized to determine whether the competition between the two genotypes could still be observed. When the proportion of genotype A was ten-fold that of B ( Fig. 6E ), competition of the two subtypes were also observed, genoype A decreased and then increased to be predominant strain.
The proportion of subtype infection (genotype A:B as 20:80, 10:100) was controlled to make B subtype dominant in the firstly passage. In genotype A:B = 20:80 group (Fig. 6B ). During the 1st passage, the proportion of genotype A rose to 34.49% but then decreased to 4.56% (P3). At the same time, the number of viral copies was maintained at approximately 5 × 10 4 . Then, the proportion of genotype A increased to 83.03% at P5 and then further increased to 99.32% (P6) and 99.98% (P8). After P9, genotype B could no longer be detected at any copy number. In genotype A:B = 10:100 group (Fig. 6D ), even when the proportion of genotype A was only one-tenth of that of B, the result was the same: the proportion of genotype A increased, decreased and increased again until we could not detect genotype B (P9). Even in the two groups with a high proportion of subtypes B, there will be a competition and alternation phenomenon first and finally genotype A will reverse to become the dominant strain. 
Discussion
hMPV is an important cause of acute respiratory illness in young children. Since it was discovered in the Netherlands in 2001, hMPV has been identified in 3-10% of hospitalized young children and has been found all over the world 1, 10 . A 10-year follow-up study on hMPV found that the annual prevalence rate ranged from 5.5-12% in Belgium between 2006 and 2016 based on the assessment of 16826 respiratory samples 32 . hMPV was most frequently discovered in late winter and spring. Two main hMPV types have been recognized (A and B), and each type has 2 subtypes (A1, A2; B1, B2) [33] [34] [35] . Research on the regular epidemiological pattern of hMPV showed that there is usually a predominant genotype of the circulating hMPV strain.
Much evidence has been gathered about the alternation of genotypes A and B. Agapov. E proposed for the first time between 2002 to 2004, the predominant circulating genotype shifted from A to B in the USA 2 . In eastern India, both group A and B viruses co-circulated in 2006-2007, but later B disappeared and genotype A became the only epidemic subtype 20 . In Korea, the predominant genotype shifted from A2a to B2 between 2007 and 2010 and then shifted back to A2b 18 . A similar alternation was also observed in Malaysia from 2010 to 2012, during which the genotype shifted from A2b to B1 and then to A2a 36 . The predominant genotype was B1 in 2004-2005, which was followed by a shift to the A2 genotype in 2006 in southeastern Brazil 19 . We also have found some reports regarding the phenomenon of subtype A/B alternation in China. Zhang C et al. observed a shift from the A2b, A1 and B1 genotypes (2008 to 2009) to the A2b genotype (2009-2011) in Chongqing 14 . These observations were consistent with those made in Beijing, which indicated that A2, B1 and B2 co-circulated, and A2 was the most prevalent genotype from 2008 to 2010 37 . The most prevalent genotype was A in 2008-2009, which shifted to B in 2010-2011 and then shifted back to A in 2012-2013 in Wuhan 22 .
We analysed the global trends in terms of hMPV subtypes, and the statistical results were consistent with those of a previous study that reported an alternating trend in the global hMPV subtypes over ten years 38 . The statistical results for the two subtypes indicated that subtypes A and B of hMPV alternate in terms of prevalence, and each epidemic can last for 1-3 years. This result was also compared with those of previous studies 2, [14] [15] [16] [17] [18] [19] [20] 29, 39, 40 . Many researchers have studied the alternation of genotype prevalence of hMPV and the most discussed reason for this phenomenon is environmental changes and human immunity 24, 41 . Viral evolution and escape are also thought to play a role in this phenomenon 42, 43 . In summary, studies of the epidemiological distribution, alternation of the genotype predominance and genetic diversity of hMPV have been conducted all over the world, but these studies have mainly involved patients with clinical manifestations of respiratory infection, and no basic research has been conducted to explain the occurrence of this phenomenon 32, 44 . Studies have shown that such alternation may be related to virus-to-host immune escape, and persistent infection or a high viral load is easily detected, which leads to the neglect of low-load subtypes. The differences in the genetic structure of hMPV and immunization against viruses caused a seasonal shift in the predominant genotype and led to the maintenance of infection rates 2, 19, 21, 35, 45, 46 . If we can determine how hMPV genotypes interact, this may be helpful for epidemic detection, treatment and prevention. We try to focus on the virus itself firstly and explore whether the interaction mechanism between A and B subtypes will affect this alternation.
In the present study, we sought to determine whether the competition exist between A and B subtypes in vivo and in vitro, and a competitive replication system was used. First, in the mouse model ( Fig. 1) , the trend of type A was down-up-down, and genotype B was predominant in the end. Except for when A:B = 80:20 during which the starting amount of genotype B was too small, the proportion of B increased slowly in the first 13d and decreased at 17d, and then increased at 20d. There may seem to have a phenomenon that no matter how virus input ratio was used, competition existed between the two subtypes and genotype B predominated in the animal models eventually. We speculated that the competitive advantage of subtype B may be related to its strong virulence 47, 48 , so we designed experiments to infect mice with A and B subtype or mixed subtypes to detect the severity of disease. However, based on our in vivo animal experiment results, the severity of illness was not related to infection with genotypes A and B in terms of weight changes (Fig. 2 ), viral load ( Fig. 3 ) airway hyperresponsiveness ( Fig. 4 ) or histopathological changes in the lungs (Fig. 5 ). This was shown not only for genotype A and B infection alone but also for 50:50, 20:80 and 80:20 mixed genotype infections. Although the results surprised us, previous clinical studies have shown that there is no difference in clinical manifestations between the two subtypes. From 2002 to 2004 in the USA, Apapov E et al. 2 first found that hMPV caused a viral genotype shift, but did not observe a difference in the severity of illness caused by various hMPV isolates. In Italy, from 2003 to 2004, Bosis S et al. 49 found that a high hMPV viral load was correlated with disease presentation, whereas the overall clinical and socioeconomic burden caused by infection with the two hMPV genotypes was similar. From 2006 to 2008 in southern Brazil, Debur MC et al. found no correlation between genotype and disease severity in inpatients and outpatients 50 . In the same period (2006) (2007) (2008) in China, no association was found between hMPV genotypes and disease severity 51 . In summary, we found that hMPV subtypes compete in vivo, but virulence is not the reason for its competitive advantages. The specific reasons need to be further explored, but we verified there is a competition between type A and B in animal at the first time, and this competition may play an alternating role in nature.
Then we performed a subtype competitive replication experiment in cells, and wanted to verify this phenomenon in vitro. In the cell model ( Fig. 6 ), different input ratios were used to infect Vero-E6 cells, and the viral titer of the two genotypes were detected. Genotype shifts were observed at input ratios of 50:50, 20:80 80:20, 10:100 and 100:10. The proportion of genotype A rose, fell and finally rose again until genotype B could not be detected. Even when A:B = 10:100 and the initial proportion of A was only 1/10 of that of B, it was also possible to gradually obtain a growth advantage and finally for A to become the predominant genotype. In the A:B = 100:10 group, due to the absolute initial proportion of genotype A being very large, the proportion of genotype A did not increase and decline but first decreased and then increased. Based on the above, in spite of the A and B genotypes having different initial proportions, the genotype ratio trends were the same; that is, the proportion of A first increased and then decreased and finally predominated. At the same time, the proportion of genotype B decreased, which was followed by an increase, until finally B disappeared at the detection end point. In summary, we observed the www.nature.com/scientificreports www.nature.com/scientificreports/ competition of the two hMPV genotypes, type A and B were alternately predominant in cell in the first four generations, and subtype A became predominant strain in the end.
There has been a contradictory phenomenon in vivo and in vitro; genotype alternation predominated was observed first and then subtype A became the predominant strain in the cell model, but genotype B predominated in animal experiment. We speculate that the reason for this disparity may be that the cell infected with virus as a simple model, and the final result is only related to the different mixing ratios of the hMPV two subtypes. In animal experiments, even if we control the external environment and diet of each group to be the same, the final result is related to the virus subtype addition ratio and the host immunity. Obviously, in animal experiments, subtype B shows a stronger adaptability. This is inconsistent with the conclusion that subtype A is the dominant strain in human 52, 53 . It may be that the hMPV dominant strain is different in different populations, or that our experiment time is too short 54, 55 . In a word, our experiments showed that the competition exist between the two subtypes and this competition could affect the alternation of genotype prevalence.
Regrettably, there were still several limitations in our experiments. First, we verified the phenomenon using a single model. We used only the Vero-E6 in vitro system and BALB/c mice for the in vivo experiments, and additional cell lines and animal models needed to be studied. Second, we monitored the animal model for only 20 days, because in previous studies, we found that the hMPV can only survive in mice for 2-3 weeks. If we find a way to extend the survival time of the hMPV in mice, the results may be more consistent with the in vitro results. Third, in animal experiments, host immunity can interfere with the impact of hMPV subtype competition on hMPV alternating epidemics. We tried to use the immunosuppressant cyclophosphamide to suppress the immunity of mice, but the use of the inhibitor caused a large number of deaths in mice. We are still looking for suitable inhibitors to suppress the immunity of mice to verify the effect of hMPV subtype competition on alternating epidemics simply. Fourth, the statistical analysis of hMPV global epidemiology may be incomplete, and some reports did not subdivide the subtypes, which may have led to insufficient data for the statistical analysis. Therefore, the actual relationships between hMPV epidemiology, disease severity and genotype alternation need to be further explored.
In summary, we found and verified that the competition between A and B subtypes exists and this competition may relate to the alternation of hMPV genotype prevalence through cell and animal experiments. Regardless of the proportions of genotypes A and B, there will be a subtype become predominant strain in the end. Subtype A predominant in vitro and subtype B in vivo experiment, and the genotype alternation observed in vitro. There were no statistically significant differences in the severity of disease caused by the two hMPV genotypes, and the severity of disease caused by mixed infection was not worse than that caused by single genotype infection. Our results may improve the understanding of the alternation of the prevalence of hMPV genotypes; perhaps this is a strategy involving genetic structure changes that is used by the virus to seasonally maintain infection rates. This study of hMPV affords us the possibility of another explanation of the hMPV alternation epidemic besides the cause of immunity, environment and climate, and it also provides experimental evidence useful for disease control and vaccine development.
Materials and Methods
Cell culture. Vero-E6 (ATCC CRL-1586) cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% foetal bovine serum (Invitrogen, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in an incubator with 5% CO 2 at 37 °C. Viral culture. hMPV NL/1/00 (virus genotype A) and NL/1/99 (virus genotype B) were kindly provided by Professor Fouchier (Erasmus Medical Center, Netherlands) and were prepared using the reverse genetics method as described previously 56, 57 . Viruses were used to infect Vero-E6 cells, which were incubated at 37 °C and cultured in DMEM in the presence of 3% FBS (Invitrogen, USA), 2 mM L-glutamine, and 5 μg/ml trypsin (Sigma, USA). Five days after infection, the culture was ultra-centrifuged at 250,000 rpm at 4 °C for 12 h using a Beckman ultracentrifuge. NL/1/00 and NL/1/99 were respectively quantified by 50% tissue culture infectious doses (TCID50) and real-time PCR. The concentrations of NL/1/00 and NL/1/99 were 10 9 copies/ml. Then, the two viral strains were mixed to generate three different proportions of hybrid virus strains at ratios of (A:B) 50:50, 20:80, 80:20, 10:100 and 100:10 on the basis of the real-time PCR results.
In vitro competitive growth experiment. The in vitro competitive growth experiments were performed with conventional Vero E6 cells. Cells in 6-well plates were inoculated with viruses at the same MOI (MOI = 50). NL/1/00, NL/1/99 and mixed virus strains of five different proportions were inoculated into six wells along with a negative control (non-infection). Then, the plates were incubated at 37 °C for 1 h to allow the virus to attach. The cells were washed with phosphate-buffered saline (PBS) to remove any unattached infectious virus particles and then overlaid with 1 ml of maintenance medium. The plates were incubated at 37 °C in 5% CO 2 . When the cytopathogenic effect (CPE) was 70%, all supernatants and plates were harvested and stored at −80 °C. One millilitre of viral media was harvested at each passage, and the supernatant was passaged into fresh Vero-E6 cells. Then, 200 μl of RNA extract was added, and the remaining volume was maintained at −80 °C. This method was used for each passage and was continued for 12 passages. After each passage, we changed the medium and harvested the supernatant for testing. All tests were performed in triplicate, and six-well plates were used.
In vivo competitive growth experiment. We carried out the test in batches because of the large number of animals. BALB/c mice (6-8 weeks old, female) were purchased from the Experimental Animal Center of Chongqing Medical University and were divided into six groups: 54 mice each experimental group(A, B, C, D, E) and 6 mice in control group(F). Each mouse was infected intranasally with 50 μl 1.0 × 10 9 copies/ml of virus after being anesthetized with chloral hydrate. Group A received NL/1/00, group B received NL/1/99, group C received a 50:50 mixture of NL/1/00 and NL/1/99, group D received a 20:80 mixture of strains, group E received a
